Moving forward with Takeda's live chimeric tetravalent dengue vaccine

Wilder-Smith, Annelies

2017

Wilder-Smith, A. (2017). Moving forward with Takeda's live chimeric tetravalent dengue vaccine. *The Lancet Infectious Diseases*, 17(6), 566-568.

<https://hdl.handle.net/10356/83617>

[https://doi.org/10.1016/S1473-3099\(17\)30165-2](https://doi.org/10.1016/S1473-3099(17)30165-2)

© 2017 Elsevier Ltd. This is the author created version of a work that has been peer reviewed and accepted for publication by *The Lancet Infectious Diseases*, Elsevier Ltd. It incorporates referee's comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [[http://dx.doi.org/10.1016/S1473-3099\(17\)30165-2](http://dx.doi.org/10.1016/S1473-3099(17)30165-2)].

Downloaded on 26 Apr 2023 21:07:19 SGT

Takeda's live chimeric tetravalent dengue vaccine: moving forward with a two-dose schedule into Phase 3 trials

Annelies Wilder-Smith

Affiliations:

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Correspondence address: Lee Kong Chian School of Medicine, Mandalay Road 11, Singapore 308232

Seven decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four serotypes (DENV1-4) for all ages. In light of the rapidly rising incidence of dengue currently estimated to clinically affect about 100 million individuals annually¹, the recent licensure of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.² However, the first vaccine does not present a simple solution. Vaccine efficacy estimates vary by prior seropositivity against dengue, infecting serotype, clinical severity, and age, with prior dengue exposure being the main determinant of vaccine efficacy.³ Furthermore, this vaccine requires three doses given six months apart - which makes programmatic roll-out and high population vaccine coverage rates difficult to achieve. Due to the higher efficacy among participants vaccinated at 9 years and older, as well as an elevated risk of hospitalized dengue in the 2-5 year age group seen transiently in the third year after vaccination, licensure was obtained in several countries only for those aged 9 and above.⁴

The performance of second-generation dengue vaccines such as those developed by Takeda⁵ is therefore avidly anticipated. In this issue of the *Lancet*, Takeda published their interim Phase 2 trial results.⁶ Similarly to CYD-TDV, Takeda's dengue vaccine (TDV) is a live attenuated chimeric tetravalent dengue vaccine. So where is the difference? Whilst Sanofi Pasteur's CYD-TDV contains four chimeric viruses (containing pre membrane and E genes of DENV-1 to 4) with yellow fever virus as the 'backbone', Takeda's TDV comprises an attenuated DENV-2 strain plus three chimeric viruses (containing prM and E genes of DENV-1, -3 and -4) cloned into an attenuated DENV-2 'backbone'. The theoretical advantage of TDV is hence that its conserved nonstructural proteins within the DENV-2 backbone may generate T-cell mediated responses to dengue infection in addition to the humoral responses to the premembrane and envelope proteins.⁷ CD8+ T cells play a key role in controlling dengue infections⁸; and TDV was shown to elicit such CD8+ T cells that were predominantly

multifunctional, producing IFN- γ and TNF- α . These multifunctional, mainly DENV-2 reactive T cells also showed some cross-protection against DENV 1, 3 and 4.⁹ However, NS1 proteins from different serotypes differ significantly in their amino acid sequences and serotype immune dominance of DENV-2 may suppress the immune response of the other serotypes, analogue to the DENV-4 serodominance seen in the Pasteur Sanofi trials.¹⁰ Hence, the question whether the above in-vitro findings will indeed translate into sustained clinical protection balanced against all four serotypes can only be answered by efficacy trials.

The study published in this issue⁶ was conducted to inform whether Takeda should progress with a one or two dose schedule into their Phase 3 efficacy trials. The primary endpoint was geometric mean titres (GMT) of neutralizing antibodies to DENV-1-4 at months 1, 3, and 6, and the main comparison was between a schedule of a single dose versus two doses 3 months apart. Consistent with previous Phase 1 and 2 studies¹¹⁻¹⁴, TDV induced by far the highest GMTs to DENV-2, followed by DENV-1, with DENV-3 and 4 associated with relatively low GMTs. The high GMT for DENV-2 is best explained by the fact that DENV-2 is the only full-genome serotype in this vaccine composition. Comparing the one and two dose schedule, GMTs were similar for seropositive and seronegative subjects combined. The secondary immunogenicity endpoint was the seropositivity rate. More than 80% of TDV-vaccinated participants in each study group had tetravalent seropositivity, and 96% or more had at least trivalent seropositivity. Even a trivalent vaccine (eg, a vaccine effective only against serotypes 1, 2 and 3, and not 4) could have a substantial benefit in terms of reducing severe disease, as in natural infections third and fourth infections tend to be mild.^{15,16}

Given that Sanofi Pasteur's CYD-TDV efficacy results were strongly driven by baseline seropositivity status, it is important to have a closer look at the subset of seronegatives in Takeda's Phase 2 trial. Indeed, similar to Sanofi Pasteur's findings, GMTs were generally lower for all serotypes for the baseline-seronegative compared with baseline-seropositive subjects, and also appeared to somewhat decline over time whilst GMTs for seropositives remained elevated over the 6 months observation. There was no difference in GMTs observed for one versus two doses for baseline-seronegatives, except in months 6 for DENV-3 and 4. This observation was also reflected by the seropositivity rates: in those who were baseline-seronegative, the two-dose schedule led to higher seropositivity rates to DENV 3 and 4 by month 6.

Previous studies showed that the T-cell response to TDV was evident after primary vaccination, did not increase by a booster vaccination, and was detectable 6 months after the last immunization.⁹ Such findings together with the fact that the GMTs and seropositivity

rates in the baseline-seropositive participants were as high after a single dose as after two doses (indicating sterilizing immunity) provide hope that a single dose schedule may be sufficient in baseline seropositive individuals. However, for population based vaccination programmes that include seropositive and seronegative individuals, there may be an advantageous edge to a two dose schedule, as a second TDV dose was needed to enhance immunogenicity against DENV-3 and -4 in baseline-seronegative children. In conclusion, the good safety profile combined with the immunogenicity findings from this trial supports moving forward to a large-scale phase 3 evaluation of efficacy and safety of TDV, using a two-dose schedule 3 months apart.

Sanofi Pasteur's well-conducted efficacy trials have taught us that good neutralizing antibody levels may not necessarily predict or induce complete vaccine efficacy.^{3,17} Although analyses of immunogenicity studies demonstrated that Sanofi Pasteur's CYD-TDV induced balanced neutralizing antibody responses to all four DENV after three doses¹⁸, these responses were insufficient to generate balanced protection against symptomatic virologically confirmed dengue.³ As Takeda's TDV was designed to induce both humoral and cellular immune responses, we are now all eagerly awaiting how the immunogenicity data derived from the investigations published in this issue of *Lancet ID* will translate into durable clinical protection (efficacy) dependent on dengue serotypes, age, and prior exposure to dengue.

References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* 2013; **496**(7446): 504-7.
2. Wilder-Smith A, Vannice KS, Hombach J, Farrar J, Nolan T. Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine. *J Infect Dis* 2016; **214**(12): 1796-9.
3. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. *N Engl J Med* 2015.
4. Wilder-Smith A, Massad E. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. *Expert Rev Vaccines* 2016; **15**(4): 437-41.
5. Osorio JE, Partidos CD, Wallace D, Stinchcomb DT. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. *Vaccine* 2015; **33**(50): 7112-20.
6. Tricou V. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine: Interim results of a long-term phase 2, randomised, placebo-controlled paediatric trial in Asia and Latin America. *Lancet ID* 2017.

7. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. *Expert Rev Vaccines* 2016; **15**(4): 497-508.
8. Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. *Proc Natl Acad Sci U S A* 2013; **110**(22): E2046-53.
9. Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD. CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate. *J Infect Dis* 2015; **212**(10): 1618-28.
10. Dorigatti I, Aguas R, Donnelly CA, et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. *Vaccine* 2015; **33**(31): 3746-51.
11. George SL, Wong MA, Dube TJ, et al. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. *J Infect Dis* 2015; **212**(7): 1032-41.
12. Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. *Lancet Infect Dis* 2014; **14**(9): 830-8.
13. Sirivichayakul C, Barranco-Santana EA, Esquelin-Rivera I, et al. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. *J Infect Dis* 2016; **213**(10): 1562-72.
14. Rupp R, Luckasen GJ, Kirstein JL, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. *Vaccine* 2015; **33**(46): 6351-9.
15. Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. *Am J Trop Med Hyg* 2007; **77**(5): 910-3.
16. Wilder-Smith A. Dengue vaccines: dawning at last? *Lancet* 2014; **384**(9951): 1327-9.
17. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet* 2014; **384**(9951): 1358-65.
18. Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. *Hum Vaccin Immunother* 2012; **8**(9): 1259-71.